Ackman Defends Valeant’s Drug Development on Investor Call

  • Investor says Valeant’s R&D programs are ‘mischaracterized’
  • Two drugs up for approval, research spending lags rivals

Why Ackman Plans to Maintain Bet Against Herbalife

Billionaire investor Bill Ackman defended Valeant Pharmaceuticals International Inc.’s research and development program, citing two drugs making their way toward the market and another just cleared.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.